Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) EVP Jeffrey L. Wade purchased 2,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Tuesday, November 14th. The shares were bought at an average cost of $9.48 per share, with a total value of $18,960.00. Following the completion of the transaction, the executive vice president now directly owns 50,597 shares of the company’s stock, valued at approximately $479,659.56. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down $0.08 during mid-day trading on Tuesday, hitting $9.73. The company’s stock had a trading volume of 888,000 shares, compared to its average volume of 804,741. Lexicon Pharmaceuticals, Inc. has a 52-week low of $8.07 and a 52-week high of $18.00. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.65 and a current ratio of 1.66.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.07. The firm had revenue of $26.94 million for the quarter, compared to the consensus estimate of $27.97 million. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The company’s revenue was down 2.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) EPS. analysts forecast that Lexicon Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/11/14/jeffrey-l-wade-purchases-2000-shares-of-lexicon-pharmaceuticals-inc-lxrx-stock.html.

Several hedge funds have recently modified their holdings of the business. FMR LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 0.9% during the 2nd quarter. FMR LLC now owns 15,785,280 shares of the biopharmaceutical company’s stock valued at $259,668,000 after acquiring an additional 137,421 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock worth $59,773,000 after acquiring an additional 585,222 shares in the last quarter. USS Investment Management Ltd bought a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter worth about $57,705,000. Eagle Asset Management Inc. raised its position in shares of Lexicon Pharmaceuticals by 0.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,861,065 shares of the biopharmaceutical company’s stock worth $47,064,000 after acquiring an additional 8,756 shares in the last quarter. Finally, State Street Corp raised its position in shares of Lexicon Pharmaceuticals by 19.9% in the 2nd quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock worth $32,363,000 after acquiring an additional 326,088 shares in the last quarter.

Several analysts have issued reports on the company. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Wedbush restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, October 5th. BidaskClub lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Needham & Company LLC reiterated a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. Finally, Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $28.75.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.